Return to search results
Sirolimus
Sirolimus, sold under the brand name Rapamune, is an oral solution (1 mg/mL) used as an immunosuppressant to reduce immune activity, often after organ transplants. It works by inhibiting mTOR and kinase pathways. Manufactured by Mylan Pharmaceuticals Inc. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Sirolimus, sold under the brand name Rapamune, is an oral solution (1 mg/mL) used as an immunosuppressant to reduce immune activity, often after organ transplants. It works by inhibiting mTOR and kinase pathways. Manufactured by Mylan Pharmaceuticals Inc. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Sirolimus",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Sirolimus — ANDA 211040 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211040"
}
]
|
| identifier | ANDA211040 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-manufacturers",
"fda",
"health-care"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Sirolimus |
